Showing 5681-5690 of 5909 results for "".
- Small-Particle Air Pollution May Raise Glaucoma Risk in Somehttps://modernod.com/news/small-particle-air-pollution-may-raise-glaucoma-risk-in-some/2479675/In people who already have a genetic vulnerability, small-particle air pollution known as black carbon may raise the risk of developing glaucoma, a new study suggests, according to a Reuters report. Researchers found that in older
- Calcified Nodules Linked to AMD Progressionhttps://modernod.com/news/calcified-nodules-linked-to-amd-progression/2479682/The presence of a specific type of calcified nodule in the retinal drusen of patients with age-related macular degeneration (AMD) is associated with a more than sixfold increased risk for late-stage progression of the disease, a study has shown, according to a Medscape
- Opternative Secures $9M in Most Recent Round of Fundinghttps://modernod.com/news/opternative-secures-9m-in-most-recent-round-of-funding/2479683/Opternative announced it has secured $9 million in its latest round of funding. The round of financing was led by Trust Ventures and Pritzker Group Venture Capital, with an additional investment from existing investor Jump Capital. Opternative will use the fun
- Eye Health America Completes Acquisition of Tampa Bay-Based Updegraff Laser Visionhttps://modernod.com/news/eye-health-america-completes-acquisition-of-tampa-bay-based-updegraff-laser-vision/2479695/Eye Health America (EHA) announced its sixth acquisition of the year, adding Updegraff Laser Vision to its roster of prominent eye care member practices in the Southeast United States. Terms of the deal were not disclosed. The acquisition of the Tampa Bay-based practice continues to
- OCT Screening Before Cataract Surgery Can Improve Outcomeshttps://modernod.com/news/oct-screening-before-cataract-surgery-can-improve-outcomes/2479699/The routine use of optical coherence tomography (OCT) to screen candidates for cataract surgery can improve surgery timing and planning, give patients realistic expectations, and even lead to changes in treatment plans, results from a new study show, according to a Medscape
- Prevent Blindness Elects Three New Members to National Board of Directorshttps://modernod.com/news/prevent-blindness-elects-three-new-members-to-national-board-of-directors-2/2479700/Prevent Blindness has announced that Paul Delatore, Global Head, Market Access at Alcon; Jim McGrann, Chairman & CEO of Healthy Eyes Advantage; and Rajeev S. Ramchandran, MD, Associate Professor of Ophthalmology in the University of Rochester Medical School’s Department of Ophthalmology, have
- Ophthalmologists Implant First Visian Toric ICLs in the UShttps://modernod.com/news/ophthalmologists-implant-first-visian-toric-icls-in-the-us/2479710/Staar Surgical announced the first patient implants of the company’s Visian Toric Implantable Collamer Lenses (TICLs) in the United States by Brinton Vision in St. Louis and Parkhurst NuVision in San Antonio. A select group of lea
- Horizon Pharma Announces Presentation of Results of 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab at AAOhttps://modernod.com/news/horizon-pharma-announces-presentation-of-results-of-48-week-off-therapy-follow-up-to-the-phase-2-trial-of-teprotumumab-at-aao/2479711/Horizon Pharma announced that more detailed results from the 48 week off-therapy follow-up to the phase 2 clinical trial of teprotumumab for people living with moderate-to-severe active thyroid eye disease (TED) were presented at the AAO annual meeting, Oct. 27–30, 2018, in Chicago. The data was
- Ophthotech Expands Retinal Disease Pipeline with Acquisition of Versant Ventures’ Inception 4https://modernod.com/news/ophthotech-expands-retinal-disease-pipeline-with-acquisition-of-versant-ventures-inception-4/2479712/Ophthotech Corporation announced that it has acquired Inception 4, a privately held company backed by Versant Ventures, expanding Ophthotech’s therapeutic pipeline in age-related retinal indications. Through this acquisition, Ophthotech gains worldwide development and commercialization rig
- Aura Biosciences Reports Positive Phase 1b/2 Clinical Data for AU-011https://modernod.com/news/aura-biosciences-reports-positive-phase-1b-2-clinical-data-for-au-011/2479713/Aura Biosciences has reported positive clinical data from its phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, its lead product candidate for the primary treatment of choroidal melanoma. “Ocular melanoma is the most